Is there an approved retatrutide dose?
No. Retatrutide is not approved by the FDA, so there is no approved dose, schedule or label. This site does not publish dosing, timing, preparation or injection instructions and has no dose calculator.
- Phase 2Published Aug 2023
- Phase 34 trials reported, Dec 2025 to Jul 2026
- SubmissionLilly plans Q1 2027. Not made yet.
- FDA reviewNo date exists
- ApprovalUnknown
A dose is approved only on an FDA-reviewed label, at the last stop of the road. Retatrutide has not reached it.
Why there is no approved dose
A dose is approved only as part of a drug's FDA-reviewed label, after the sponsor submits evidence on safety and effectiveness. Lilly has said it plans to submit retatrutide in the first quarter of 2027 (Lilly release, 2026-07-23). No submission has been reported and no FDA review has happened. The FDA says retatrutide has "not been found safe and effective for any condition" (FDA, current as of 2026-10-01).
What "4 mg, 9 mg, 12 mg" means in the news
Trial reports name their arms by dose: 4 mg, 9 mg and 12 mg in TRIUMPH-1 and TRIUMPH-2, 9 mg and 12 mg in TRIUMPH-3 and TRIUMPH-4. Those are labels for what the sponsor tested, in supervised studies, in specific groups of people. They are not recommended doses. A trial's results can differ by arm in both benefit and tolerability; see each trial's figures on the trial evidence index, and do not compare arms across different trials.
Why online dosing guides are not a safe source
- They are not based on an FDA-reviewed label, because none exists.
- Products sold as "research" retatrutide are not FDA-approved. The FDA describes such products as "of unknown quality" that "may be harmful to their health." Their contents and strength cannot be assumed.
- The FDA has pointed to dosing instructions sold with these products as part of why "research use only" labels do not hold up. See the legal section of the status page.
If you are already taking an unapproved product, talk to a licensed clinician or pharmacist, or call Poison Control at 1-800-222-1222 if you think you are in danger. You can report a reaction to the FDA through MedWatch.
Frequently asked questions
Is there an FDA-approved retatrutide dose?
No. Retatrutide is not approved, so no dose, schedule or product label exists. FDA material current as of 2026-10-01 says it has not been found safe and effective for any condition.
What do 4 mg, 9 mg and 12 mg mean in the trial results?
They are the names of study arms in Eli Lilly's clinical trials. Participants were assigned to an arm under medical supervision and monitored. The labels describe what was tested. They are not recommendations.
Why not publish a dosing schedule?
Because none has been approved. A schedule from a trial protocol is not a prescription, and the FDA has cited dosing guidance sold with research peptides as evidence that sellers intend human use.
Last checked . Independent summary of published sources. Editorial policy and corrections